FDA Plays Nicely: Fibrocell Laviv Review Drew From Three Centers
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Fibrocell’s autologous cell therapy Laviv was reviewed by CBER with significant help from CDER and CDRH, providing a model of how FDA can handle high-tech products that cross traditional boundaries.
You may also be interested in...
Review Of Reviews: Drug Review Profiles Of 2011
Each month, Pharmaceutical Approvals Monthly analyzes the FDA review process for a recent approval based on the NDA or BLA review documents. A detailed chronology of product development and listing of key reviewers accompany each profile.
Companion Diagnostics: A Business Area Fraught With Challenges Ahead
The challenges of developing and utilizing companion diagnostics were on the minds of attendees at the Cancer Progress meeting in New York.
US FDA Expects Joint AdComm Briefing Document, Oncology Chief Says
The combined format is the new default for briefing advisory committee members, US FDA Oncology Center of Excellence Director Pazdur declared.